Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Mahendra

Showing results (61-70 of 64) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 64 results.
Leukemia Research|February 12, 2013
Post-transplant T cell chimerism predicts graft versus host disease but not disease relapse in patients undergoing an alemtuzumab based reduced intensity conditioned allogeneic transplantE Nikolousis, S Robinson, S Nagra, et al.
Cytotherapy|August 13, 2002
Allogeneic stem-cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH (+/- fludarabine) conditioning combined with post-transplant donor-lymphocyte infusionR J Lush, A P Haynes, J Byrne, et al.
Cytotherapy|August 13, 2002
In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantationP D Kottaridis, D W Milligan, R Chopra, et al.
Blood|September 26, 2000
In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantationP D Kottaridis, D W Milligan, R Chopra, et al.
Pageof 7

Showing results (61-70 of 64) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 64 results.
Leukemia Research|February 12, 2013
Post-transplant T cell chimerism predicts graft versus host disease but not disease relapse in patients undergoing an alemtuzumab based reduced intensity conditioned allogeneic transplantE Nikolousis, S Robinson, S Nagra, et al.
Cytotherapy|August 13, 2002
Allogeneic stem-cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH (+/- fludarabine) conditioning combined with post-transplant donor-lymphocyte infusionR J Lush, A P Haynes, J Byrne, et al.
Cytotherapy|August 13, 2002
In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantationP D Kottaridis, D W Milligan, R Chopra, et al.
Blood|September 26, 2000
In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantationP D Kottaridis, D W Milligan, R Chopra, et al.
Pageof 7